RESUMEN
Highly effective modulator therapies (HEMTs) have revolutionised the management approach of most patients living with cystic fibrosis (CF) who have access to these therapies. Clinical trials have reported significant improvements across multiorgan systems, with patients surviving longer. However, there are accumulating case reports and observational data describing various adverse events following initiation of HEMTs including drug-to-drug interactions, drug induced liver injury, Stevens-Johnson syndrome, and neurocognitive symptoms including psychosis and depression, which have required discontinuation of therapy. Current clinical trials are assessing efficacy in younger patients with CF, yet long-term studies are also required to better understand the safety profile in the real-world setting across all ages and the impact of HEMT dose alteration or discontinuation.
Asunto(s)
Fibrosis Quística , Humanos , Fibrosis Quística/tratamiento farmacológico , Cognición , Regulador de Conductancia de Transmembrana de Fibrosis Quística , Mutación , Aminofenoles , Agonistas de los Canales de CloruroRESUMEN
Cystic Fibrosis-Related Diabetes (CFRD) is a unique type of diabetes mellitus that shares some features with both type 1 and type 2 diabetes. Yet, its distinguishing feature of acute pulmonary complications associated with hyperglycemia and the catabolic metabolism associated with a relative insulin deficiency poses challenges to the application of traditional definitions and treatments for diabetes mellitus. People with CF (pwCF) undergo rigorous annual screening starting at age 10, a process that is challenging for patients and limited by sensitivity, specificity, and reproducibility. As pwCF continue to live longer, over 50% are expected to develop CFRD over their lifetime, including up to 20% of adolescents. Increasing numbers of people with CFRD will make this disease increasingly relevant to diabetes practitioners. Evidence-guided practice in CFRD care is limited by small and short studies. Our current understanding of CFRD may change significantly with the recent introduction of CF Transmembrane Regulator (CFTR) modulator medications. This review will explore current challenges in the diagnosis and management of CFRD, specifically highlighting knowledge gaps in the pathophysiology of CFRD, optimal screening methods, priorities for research and provide guidance with regards to screening, diagnosis, and treatment.
Asunto(s)
Fibrosis Quística , Diabetes Mellitus Tipo 2 , Diabetes Mellitus , Adolescente , Humanos , Niño , Fibrosis Quística/terapia , Fibrosis Quística/tratamiento farmacológico , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Reproducibilidad de los Resultados , Insulina/uso terapéutico , Tamizaje Masivo , Diabetes Mellitus/epidemiología , Diabetes Mellitus/etiología , Diabetes Mellitus/diagnósticoRESUMEN
The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.
Asunto(s)
Fibrosis Quística , Diabetes Mellitus , Fibrosis Quística/complicaciones , Fibrosis Quística/diagnóstico , Fibrosis Quística/epidemiología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/epidemiología , Humanos , PulmónRESUMEN
It is not yet known whether continuous glucose monitoring (CGM) abnormalities persist in young children with CF. We evaluated longitudinal CGM results for children with CF < 10 years of age. We performed 3-day CGM at baseline, 12 months, and 24 months on 11 CF children (1 female) initially aged mean (SD) 3.8 (2.5) years. CGM analysis included (i) mean sensor glucose (SG), (ii) standard deviation (SD) for SG, (iii) peak SG and (iv)% time spent above a threshold of 7.8 mmol/L. Only three (3/11, 27%) had normal CGM at all time-points. Nearly three quarters of the participants (8/11, 73%) spent more than 4.5 percent time > 7.8 mmol/L at one time-point, five of whom had an elevated percent time on a subsequent test. Young children with CF have glucose abnormalities detected by CGM that fluctuate over time.
Asunto(s)
Fibrosis Quística/complicaciones , Fibrosis Quística/metabolismo , Intolerancia a la Glucosa/diagnóstico , Factores de Edad , Automonitorización de la Glucosa Sanguínea , Niño , Preescolar , Líquido Extracelular/metabolismo , Femenino , Glucosa/metabolismo , Intolerancia a la Glucosa/etiología , Intolerancia a la Glucosa/metabolismo , Humanos , Estudios Longitudinales , Masculino , Estudios Prospectivos , Factores de TiempoRESUMEN
BACKGROUND: Screening for Cystic Fibrosis-related diabetes is recommended in patients with CF <10â¯years old when there are concerns about growth and lung function. The Oral Glucose Tolerance Test (OGTT) is recommended but has not been validated in this cohort. We sought to determine whether the 2-h OGTT, the gold standard diagnostic test for CFRD, detects clinical decline in children with CF <10â¯years old. METHODS: We analysed blood glucose(BG) levels collected every 30â¯min during OGTT in 27 children with CFâ¯<â¯10â¯years old, comparing the 2-hour BG (BG120min), peak BG (BGmax) and Area Under the Curve(AUC) for glucose and the association with lung function and nutritional status. We also compared the OGTT results with results from Continuous Glucose Monitoring (CGM) performed in 11 participants. RESULTS: The BGmax was higher than the BG120min in 25/27 (93%) participants. There was a significant inverse correlation between BGmax and weight z-score (rsâ¯=â¯-0.56, pâ¯=â¯.002) and between BGmax and FEV1 (rsâ¯=â¯-0.54, pâ¯=â¯.014) that was not present for BG120min. A significant inverse correlation was also identified between fasting insulin level and elevated glucose on CGM, defined as AUC >7.8â¯mmol/L (rs =â¯-â¯0.69, pâ¯=â¯.027) or as % timeâ¯>â¯7.8 (rsâ¯=â¯- 0.76, pâ¯=â¯.011). CONCLUSIONS: Children with CFâ¯<â¯10â¯years of age with higher BGmax on OGTT have lower lung function and weight z- scores that may not be identified using the 2â¯h OGTT BG120min. CGM also identifies glucose excursions in young children with CF.
Asunto(s)
Glucemia/análisis , Fibrosis Quística , Diabetes Mellitus , Intolerancia a la Glucosa , Prueba de Tolerancia a la Glucosa/métodos , Insulina/sangre , Automonitorización de la Glucosa Sanguínea/métodos , Niño , Desarrollo Infantil , Correlación de Datos , Fibrosis Quística/sangre , Fibrosis Quística/complicaciones , Fibrosis Quística/fisiopatología , Diabetes Mellitus/sangre , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/etiología , Femenino , Intolerancia a la Glucosa/sangre , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/etiología , Humanos , Masculino , Tamizaje Masivo/métodos , Estado Nutricional , Pruebas de Función Respiratoria/métodosRESUMEN
BACKGROUND: Children with cystic fibrosis (CF) are routinely managed in a multidisciplinary clinic at tertiary pediatric centers. However, children with bronchiectasis may not be managed in the same way. We sought to compare the management model and clinical outcomes of children with bronchiectasis with children diagnosed with CF, in a single pediatric center. METHODS: We identified patients with bronchiectasis from hospital medical records at an urban tertiary pediatric hospital and identified a sex- and age-matched CF patient at the same center to compare lung function, nutritional status, frequency of physiotherapy and respiratory physician visits, and number of microbiological samples taken for bacterial culture. RESULTS: Twenty-two children with bronchiectasis were identified, mean (standard deviation [SD]) age was 11 (3) years. The most common known etiology for bronchiectasis was postinfective (6 of 22) but was unknown in 8 of 22. The cohort with bronchiectasis had poorer lung function (FEV1 mean [SD] percent predicted 78.6 [20.5] vs 94.5 [14.7], P = .005) and had less outpatient reviews by the respiratory physician (P < .001) and respiratory physiotherapist (P < .001) when compared to those with CF. Nutritional parameters did not differ between the groups. Many children (10 of 22, 45%) with bronchiectasis did not have any microbiological respiratory tract samples taken for evaluation. CONCLUSION: Children with bronchiectasis at this institution have poorer lung function than children with CF, and are deserving of improved multidisciplinary care.
Asunto(s)
Bronquiectasia/terapia , Fibrosis Quística/terapia , Pulmón/fisiopatología , Nivel de Atención , Adolescente , Bronquiectasia/fisiopatología , Niño , Preescolar , Estudios de Cohortes , Fibrosis Quística/fisiopatología , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Children with CF are insulin deficient from infancy but very little is known about the impact of glucose abnormalities in early life. We aimed to identify and describe interstitial glucose levels in CF children <6â¯years and to evaluate the association with pulmonary infection and inflammation. METHODS: We assessed 18 children (5 females) with median age of 3.2â¯years (range 0·9-5.5) with Continuous Glucose Monitoring for 3â¯days. Bronchoalveolar lavage (BAL) fluid was cultured for known pathogenic microbial agents and assessed for total white blood cells, percentage of neutrophils and IL-8 level. RESULTS: Peak sensor glucose (SG) was >11.1â¯mmol/L in 39% of participants. The percentage neutrophil count on BAL was positively correlated with elevated SG (peak SG rsâ¯=â¯0.48, pâ¯=â¯.044) and with glucose variability (SG standard deviation râ¯=â¯0.62, ßâ¯=â¯38.5, pâ¯=â¯.006). BAL IL-8 level was significantly correlated with all measures of CGM hyperglycemia including % timeâ¯>â¯7.8â¯mmol/L (pâ¯=â¯.008) and standard deviation (pâ¯<â¯.001). Participants with a history of Pseudomonas aeruginosa had a higher % timeâ¯>â¯7.8â¯mmol/L glucose (16% versus 3%, pâ¯=â¯.015). CONCLUSION: Children with CF frequently demonstrate elevated SG levels before age 6â¯years, which are associated with increased pulmonary inflammation and Pseudomonas aeruginosa infection. Transient SG elevations into the diabetic range (≥11.1â¯mmol/L) were identified in children from 1â¯year of age.